CHOLBAM

Peak

cholic acid

NDAORALCAPSULEPriority Review
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
17

Mechanism of Action

liver. In bile acid synthesis disorders due to SEDs in the biosynthetic pathway, and in PDs including Zellweger spectrum disorders, deficiency of primary bile acids leads to unregulated accumulation of intermediate bile acids and cholestasis. Bile acids facilitate fat digestion and absorption by…

Pharmacologic Class:

Bile Acid

Clinical Trials (5)

NCT06383403Phase 3Active Not Recruiting

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Started Jul 2024
69 enrolled
Primary Biliary Cholangitis
NCT06260748Phase 3Withdrawn

A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

Started May 2024
0
Cerebrotendinous Xanthomatoses
NCT05133830Phase 1Completed

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

Started Nov 2021
52 enrolled
Pruritus
NCT04956328Phase 3Unknown

Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)

Started Jul 2021
NCT04620733Phase 3Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Started Apr 2021
193 enrolled
Primary Biliary Cholangitis